

This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, as amended, but is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.

Subject to Completion, Dated February 13, 2024

Preliminary Prospectus Supplement  
(To Prospectus dated December 19, 2023)

**12,000,000 Shares**



**REV Group, Inc.**

**Common Stock**

The selling stockholders identified in this prospectus supplement are offering 12,000,000 shares of our common stock. We will not receive any proceeds from the sale of common stock by the selling stockholders.

Subject to the completion of this offering and assuming the underwriters purchase 12,000,000 shares of our common stock, we intend to purchase from the underwriters 6,000,000 of the shares of our common stock that are subject to this offering at a price per share equal to the price per share paid by the underwriters to the selling stockholders in this offering. The completion of the share repurchase is conditioned upon, among other things, the completion of this offering.

Our shares of common stock are listed on the New York Stock Exchange ("NYSE") under the symbol "REVG." On February 12, 2024, the last reported sale price of our common stock as reported on the NYSE was \$17.49 per share.

The underwriters expect to deliver the shares of common stock to investors on or about \_\_\_\_\_, 2024.

**Baird**

**Goldman Sachs & Co. LLC**

**Morgan Stanley**

Prospectus Supplement dated \_\_\_\_\_, 2024.

#### USE OF PROCEEDS

We will not receive any proceeds from the sale of shares of our common stock by the selling stockholders. See "Selling Stockholders."

S-13

shares.

The selling stockholders have granted to the underwriters an option, exercisable for 30 days from the date of this prospectus supplement, to purchase up to 1,800,000 additional shares at the public offering price less any underwriting discount. Any shares issued or sold under the option will be issued and sold on the same terms and conditions as the other shares that are the subject of this offering.

In connection with the offering, the underwriters may purchase and sell our common stock in the open market. These transactions may include short sales, purchases on the open market to cover positions created by short sales and stabilizing transactions. Short sales involve the sale by the underwriters of a greater number of shares than it is required to purchase in the offering. "Covered" short sales are sales made in an amount not greater than the underwriters' option to purchase additional shares described above. The underwriters may close out any covered short position by either exercising its option to purchase additional shares or purchasing shares in the open market. In determining the source of shares to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase shares through the option granted to them. "Naked" short sales are sales in excess of such option. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of our common stock in the open market after pricing that could adversely affect investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of shares of common stock made by the underwriters in the open market prior to the completion of the offering.